Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. It is grouped under the following drug class(es): Androgen receptor inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Nubeqa, Darolutamida and Darolutamidum. Its PubChem CID is 67171867.
Darolutamide
| CAS No | 1297538-32-9 |
|---|---|
| Molecular Formula | C19H19ClN6O2 |
| Molecular Weight | 398.8 g/mol |
| Synonyms | N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists.
The listed CAS number is 1297538-32-9.
The listed molecular formula is C19H19ClN6O2.
The listed molecular weight is 398.8 g/mol.
N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide.
The source lists Nubeqa, Darolutamida and Darolutamidum.